Phase 3
once daily, oral
Monoamine reuptake · Abbott
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Obesity pipeline
Programs by company or class, across phase, filing, approval, and a stop.
83 of 94 programs on this matrix
| Phase 2 | Phase 3 | Filed | Approved | Discontinued | Stage n/r | |
|---|---|---|---|---|---|---|
| Abbott1 program | Phase 3 once daily, oral Monoamine reuptake · Abbott | |||||
| AbbVie1 program | Phase 2 oral and injection Amylin · AbbVie | |||||
| Aconcagua Bio, Inc1 program | Phase 1/2 oral Amylin · Aconcagua Bio, Inc | |||||
| Altimmune1 program | Phase 2 once weekly GLP-1/glucagon · Altimmune | |||||
| Amgen1 program | Registry, Jan 21, 2027 subcutaneous, subcutaneous GLP-1 conjugate · Amgen | |||||
| Arrowhead1 program | Registry, Feb 2027 Dosing n/r Class not reported · Arrowhead | |||||
| Ascletis Pharma (China) Co1 program | Phase 3 once daily, oral and injection Class not reported · Ascletis Pharma (China) Co | |||||
| AstraZeneca4 programs | Registry, Nov 18, 2026 once daily, oral Oral small molecule · AstraZeneca Phase 3 twice daily, oral and injection GLP-1 RA · AstraZeneca Phase 2/3 weekly, oral and injection Amylin · AstraZeneca Registry, May 4, 2027 weekly, oral and injection Class not reported · AstraZeneca | |||||
| Biohaven Therapeutics1 program | Phase 2 once weekly, injection Class not reported · Biohaven Therapeutics | |||||
| Boehringer Ingelheim1 program | Registry, Dec 8, 2026 once weekly, subcutaneous GLP-1/glucagon · Boehringer Ingelheim | |||||
| BrightGene Bio-Medical Technology Co1 program | Registry, Feb 28, 2027 once weekly, oral and injection GLP-1/GIP · BrightGene Bio-Medical Technology Co | |||||
| Carmot Therapeutics, Inc1 program | Phase 2 once daily, injection Class not reported · Carmot Therapeutics, Inc | |||||
| Company n/r3 programs | Phase 3 once weekly, injection GLP-1 RA · Company n/r Phase 2/3 injection Class not reported · Company n/r | Stage n/r once weekly, injection GLP-1 RA · Company n/r | ||||
| CSPC Baike (Shandong) Biopharmaceutical Co1 program | Phase 3 once weekly, injection GLP-1 RA · CSPC Baike (Shandong) Biopharmaceutical Co | |||||
| Eli Lilly7 programs | Phase 2 Dosing n/r Class not reported · Eli Lilly Registry, Dec 31, 2028 weekly, injection Myostatin/activin · Eli Lilly | Registry, Mar 14, 2027 once weekly, subcutaneous GIP/GLP-1/glucagon · Eli Lilly Registry, Mar 2028 once weekly, subcutaneous Amylin · Eli Lilly Phase 3 weekly, injection Class not reported · Eli Lilly | Registry, Jan 2027 once weekly, subcutaneous GLP-1/GIP · Eli Lilly Registry, Sep 6, 2027 once daily, tablet Oral small molecule · Eli Lilly | |||
| Empros Pharma AB1 program | Approved once monthly, oral Lipase inhibitor · Empros Pharma AB | |||||
| Fujian Shengdi Pharmaceutical Co1 program | Registry, Oct 31, 2027 once weekly, oral and injection GLP-1/GIP · Fujian Shengdi Pharmaceutical Co | |||||
| Gan & Lee Pharmaceuticals1 program | Registry, Jun 30, 2027 every 4 weeks, injection GLP-1 RA · Gan & Lee Pharmaceuticals | |||||
| Gasherbrum Bio, Inc1 program | Phase 3 once daily, oral Oral small molecule · Gasherbrum Bio, Inc | |||||
| GSK1 program | Phase 3 once weekly, oral and injection Class not reported · GSK | |||||
| Guangdong Raynovent Biotech Co1 program | Phase 3 once weekly, oral and injection Class not reported · Guangdong Raynovent Biotech Co | |||||
| Hangzhou Sciwind Biosciences Co1 program | Registry, Jan 5, 2027 once weekly, oral and injection GLP-1 RA · Hangzhou Sciwind Biosciences Co | |||||
| Hengrui1 program | Phase 3 once daily, oral and injection Class not reported · Hengrui | |||||
| Huadong Medicine3 programs | Phase 3 once daily, oral GLP-1 RA · Huadong Medicine Phase 3 once weekly, injection Class not reported · Huadong Medicine Registry, Dec 2026 once weekly, injection GLP-1/GIP · Huadong Medicine | |||||
| Innovent1 program | Registry, Dec 31, 2026 once weekly, oral and injection GLP-1 RA · Innovent | |||||
| Inversago Pharma1 program | Phase 2 once daily, oral CB1 · Inversago Pharma | |||||
| MindRank AI Ltd1 program | Phase 3 oral Small molecule · MindRank AI Ltd | |||||
| NeuroSearch1 program | Phase 2 daily Monoamine reuptake · NeuroSearch | |||||
| Novo Nordisk9 programs | Phase 2 once weekly, oral and injection Class not reported · Novo Nordisk Phase 2 once weekly, injection Class not reported · Novo Nordisk Phase 1/2 once monthly, oral and injection Serotonin agonist · Novo Nordisk | Registry, Jun 12, 2028 once weekly, oral and injection Class not reported · Novo Nordisk Registry, Feb 22, 2028 once daily, oral GLP-1 RA · Novo Nordisk Registry, Jan 26, 2027 once weekly, injection Amylin · Novo Nordisk | Registry, Mar 2027 once weekly, injection Amylin combo · Novo Nordisk | Registry, Sep 6, 2028 once weekly, injection and tablet GLP-1 RA · Novo Nordisk Approved once daily, oral and injection GLP-1 RA · Novo Nordisk | ||
| Orexigen Therapeutics, Inc1 program | Registry, Dec 31, 2030 daily Opioid and antidepressant · Orexigen Therapeutics, Inc | |||||
| PegBio Co1 program | Phase 1/2 once weekly, injection Class not reported · PegBio Co | |||||
| Pfizer4 programs | Phase 1/2 every 4 weeks, injection Class not reported · Pfizer Phase 2 once daily, oral Class not reported · Pfizer Phase 2 daily, oral and injection GLP-1 RA · Pfizer | Registry, Sep 21, 2027 once weekly, injection Class not reported · Pfizer | ||||
| Regeneron3 programs | Phase 2 injection Myostatin/activin · Regeneron Studied in NCT06299098 Dosing n/r Class not reported · Regeneron | Registry, Nov 13, 2026 once weekly, injection Class not reported · Regeneron | ||||
| Rhythm2 programs | Phase 2 daily, oral Class not reported · Rhythm | Registry, Mar 13, 2027 once daily, injection MC4R · Rhythm | ||||
| Roche3 programs | Registry, Oct 20, 2028 once weekly, injection Amylin · Roche Phase 3 once weekly GLP-1 RA · Roche Registry, Nov 12, 2027 once weekly, injection GLP-1/GIP · Roche | |||||
| Sanofi3 programs | Phase 3 once daily, oral and injection GLP-1 RA · Sanofi Phase 3 once daily, oral CB1 · Sanofi Phase 3 once weekly, oral and injection Class not reported · Sanofi | |||||
| Scholar Rock1 program | Phase 2 every 4 weeks, injection Myostatin/activin · Scholar Rock | |||||
| Shandong Suncadia Medicine Co1 program | Phase 3 oral Oral small molecule · Shandong Suncadia Medicine Co | |||||
| Shanghai Yinnuo Pharmaceutical Technology Co1 program | Registry, Nov 30, 2026 once weekly, injection GLP-1 RA · Shanghai Yinnuo Pharmaceutical Technology Co | |||||
| Shanghai Yinnuo Pharmaceutical Technology Co.1 program | Phase 2/3 weekly, oral and injection GLP-1 RA · Shanghai Yinnuo Pharmaceutical Technology Co. | |||||
| Shionogi1 program | Phase 2 once daily, oral Class not reported · Shionogi | |||||
| Skye Bioscience1 program | Registry, Nov 20, 2026 injection Class not reported · Skye Bioscience | |||||
| Terns, Inc1 program | Phase 2 once daily Oral small molecule · Terns, Inc | |||||
| The United Bio-Technology (Hengqin) Co1 program | Registry, Jan 14, 2027 once weekly, oral and injection GIP/GLP-1/glucagon · The United Bio-Technology (Hengqin) Co | |||||
| Verdiva Bio Dev Limited1 program | Phase 2 weekly, oral Class not reported · Verdiva Bio Dev Limited | |||||
| Veru Inc1 program | Phase 2 weekly, oral and injection SARM · Veru Inc | |||||
| Viking Therapeutics2 programs | Registry, Jul 2027 once weekly, subcutaneous GLP-1/GIP · Viking Therapeutics Phase 3 once daily, oral GLP-1/GIP · Viking Therapeutics | |||||
| Vincentage Pharma Co1 program | Phase 3 once daily, oral Oral small molecule · Vincentage Pharma Co | |||||
| VIVUS1 program | Phase 3 once daily, oral and injection Sympathomimetic combo · VIVUS | |||||
| Zafgen1 program | Phase 3 weekly, injection MetAP2 inhibitor · Zafgen | |||||
| Zealand Pharma1 program | Phase 2 once weekly, injection GLP-1 RA · Zealand Pharma |